Short answer
EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on August 17, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Topline LUGANO Phase 3 data announced for DURAVYU in wet AMD.
EyePoint, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Topline LUGANO Phase 3 data announced for DURAVYU in wet AMD
- Results represent a pivotal clinical milestone with potential regulatory and commercial implications
- Updated investor presentation provides additional program context and outlook
- Detailed efficacy and safety results are in Exhibits 99.1 and 99.2
Item EX-99.1 · Exhibit EX-99.1
- LUGANO’s full-dataset primary endpoint failed, creating regulatory and investor risk despite favorable secondary outcomes
- Ad hoc analysis excluding 9 of 211 patients with unrelated vision loss showed non-inferiority versus aflibercept, nominal p=0.0096
- DURAVYU reduced treatment burden 42%, equivalent to two fewer injections through Week 56 versus aflibercept
- 54% remained supplement-free through Week 56, while 79% received zero or one supplement
- LUCIA topline data expected Q4 2026, with potential NDA submission targeted for 1H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other EyePoint, Inc. 8-K filings
Get the next EYPT 8-K as it lands
Follow EYPT for push alerts, or ask the research agent what this filing means.